Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Corporate Update and Revised Investor Presentation

22 May 2014 07:00

RNS Number : 7579H
Fastnet Oil & Gas PLC
22 May 2014
 



 22 May 2014

  

Fastnet Oil & Gas Plc

Corporate Update and Revised Investor Presentation

 

Ahead of investor meetings today, Fastnet (AIM: FAST, ESM: FOI), the E&P company focused on exploring in Africa and in the Celtic Sea, is pleased to provide an update on its operations, including its proposed forward work programmes and farm-out activities.

 

An updated corporate presentation is now available on the Company's website (http://www.fastnetoilandgas.com/investor-relations/presentations/2014.aspx) providing an overview of the Company's recent corporate developments and its asset portfolio.

 

Morocco

Foum Assaka

· Foum Assaka Offshore project costs net to Fastnet from licence acquisition through prospect portfolio development to the completion of the first exploration well (FA-1) are less than USD $2.75m

 

· The Company's in-house post well studies are encouraging for continued evaluation of the hydrocarbon prospectivity of the block

 

· The FA-1 and Cairn's FD-1 Foum Draa wells are "range-finding" wells that allow us to better focus on the main reservoir fairways

 

· Pre-stack Depth Migration can now be constrained and calibrated by actual well velocities

 

· Seismic amplitude "technology" driven definition of exploration prospects pre-drill can now be better calibrated based on actual well data tied to a better understanding of seismic sequence stratigraphy

 

· The Early Cretaceous remains an important target in Foum Assaka based on analogies with the Moroccan conjugate margin equivalent of Nova Scotia where this interval is the main focus of attention for the oil majors

 

· Management believes all aspects of the petroleum system have now been de-risked with the exception of reservoir thickness and quality which remains the main challenge to address pre-drill

Tendrara

· The pre-stack depth migration reprocessing is expected to be completed in the coming weeks and this will allow us to refine our TE-6 well location and design

 

Celtic Sea

Deep Kinsale

· 3D seismic confirms five potential reservoir targets with potential for substantial in-place oil based on structural size, up to 140 sq. km., and presence of oil logged in legacy wells 48/20-1a and 48/25-1

 

· 3D seismic has confirmed potential for reservoir development and has significantly reduced the risk of reservoir compartmentalisation, two legacy issues that have previously held back farmout efforts, which were based only on limited 2D seismic coverage

 

Mizzen

· 3D seismic confirms potential for a new frontier exploration basin that is the conjugate margin equivalent of the Flemish Pass and Jeanne d'Arc Basins of Eastern Canada, which hold large hydrocarbon fields and recent discoveries

 

· 3D seismic has defined new amplitude-supported potential gas structures and large stratigraphic traps

 

· Multiple prospects and leads with potential for multi-TCF in-place gas

 

· A two-stage farmout process is underway with increased interest following the highly successfully Celtic Sea Conference held in Dublin in April.

 

Funding

· Current Cash Balance of USD $22m

 

· Fully funded for planned work programmes in Morocco and Ireland

 

· Second well carry in Foum Assaka, subject to USD$100m cap, in the event of an appraisal well or, at SK's discretion, a further exploration well

 

· Up to USD$20m of past costs in the Celtic Sea potentially recoverable subject to a successful first stage farmout

 

Commenting, Paul Griffiths, Managing Director of Fastnet, said:

 

"In challenging times for the oil and gas sector we are satisfied that Fastnet is prudently managing its cash resources whilst still creating momentum in developing its portfolio of offshore and onshore assets to a stage where drilling can occur. The FA-1 well represented a high risk - high reward drilling opportunity that was executed with minimal financial risk to Fastnet shareholders through a prudent and successful farmout process. Whilst high risk - high reward drilling opportunities continue to be developed in Foum Assaka following FA-1, the remainder of the portfolio, which contains much lower risk but equally high reward multiple prospects, continues to be matured ready for drilling. We will pursue our strategy of reducing our financial exposure to drilling through a tried and tested farmout process on the basis that exposure to sustained drilling activity offers the best opportunity to create substantial value through the drill bit."

 

 For further information, please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

 

GMP Securities Europe LLP

(Joint Broker)

Rob Collins, Emily Morris, Liz Williamson

 

+44 (20) 20 7467 2800

Davy

(ESM Adviser & Joint Broker)

John Frain

Anthony Farrell

 

+353 (1) 679 6363

 

Bell Pottinger

Philip Dennis, Rollo Crichton-Stuart, Jimmy Lea

 

+44 (0) 207 861 3232

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMGZKRMFGDZM
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.